Citadel Advisors
ALDX icon

Citadel Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Citadel Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,600
Closed -$45K – 13612
2026
Q1 		$45K Sell
26,600
-95,100
-78% -$417K ﹤0.01% 12437
2025
Q4 		$630K Buy
121,700
+106,200
+685% +$546K ﹤0.01% 8458
2025
Q3 		$80.9K Buy
+15,500
New +$80.8K ﹤0.01% 11968
2025
Q2 		– Sell
-19,600
Closed -$113K – 12372
2025
Q1 		$113K Sell
19,600
-44,900
-70% -$265K ﹤0.01% 11296
2024
Q4 		$322K Sell
64,500
-4,900
-7% -$25.1K ﹤0.01% 9510
2024
Q3 		$374K Buy
69,400
+36,900
+114% +$176K ﹤0.01% 8853
2024
Q2 		$108K Buy
32,500
+3,800
+13% +$14.9K ﹤0.01% 10815
2024
Q1 		$93.8K Sell
28,700
-37,500
-57% -$123K ﹤0.01% 11444
2023
Q4 		$232K Sell
66,200
-49,900
-43% -$154K ﹤0.01% 9650
2023
Q3 		$776K Sell
116,100
-25,300
-18% -$188K ﹤0.01% 7115
2023
Q2 		$1.19M Sell
141,400
-49,500
-26% -$488K ﹤0.01% 6105
2023
Q1 		$1.9M Buy
190,900
+78,700
+70% +$556K ﹤0.01% 5493
2022
Q4 		$781K Buy
112,200
+100,500
+859% +$575K ﹤0.01% 7310
2022
Q3 		$62K Sell
11,700
-12,400
-51% -$74.4K ﹤0.01% 11470
2022
Q2 		$96K Sell
24,100
-33,000
-58% -$113K ﹤0.01% 11443
2022
Q1 		$254K Sell
57,100
-52,700
-48% -$210K ﹤0.01% 10959
2021
Q4 		$439K Buy
109,800
+87,200
+386% +$665K ﹤0.01% 10002
2021
Q3 		$198K Sell
22,600
-175,900
-89% -$1.61M ﹤0.01% 11991
2021
Q2 		$2.25M Buy
198,500
+22,200
+13% +$267K ﹤0.01% 6306
2021
Q1 		$2.09M Buy
176,300
+162,300
+1,159% +$1.87M ﹤0.01% 6275
2020
Q4 		$96K Buy
+14,000
New +$98.3K ﹤0.01% 10245
2020
Q3 		– Sell
-10,700
Closed -$45K – 10020
2020
Q2 		$45K Buy
+10,700
New +$39.1K ﹤0.01% 9348
2019
Q2 		– Sell
-45,200
Closed -$408K – 9108
2019
Q1 		$408K Buy
+45,200
New +$384K ﹤0.01% 7124

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Citadel Advisors's ALDX Position: Q2 2026 in Review

Citadel Advisors increased its Aldeyra Therapeutics (ALDX) stake by 42% in Q2 2026, buying an estimated $194K and bringing the position to 379,144 shares worth $808K. The position accounts for ﹤0.01% of the portfolio, ranked #8732.

Citadel Advisors first reported a position in ALDX in Q1 2018 and has held it in 31 quarters since. The position peaked at $11M in Q1 2022. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Citadel Advisors held 379,144 shares of Aldeyra Therapeutics worth $808K as of Q2 2026.
  • Citadel Advisors bought 112,804 Aldeyra Therapeutics shares in Q2 2026, an estimated $194K.
  • Aldeyra Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8732 holding.
  • Citadel Advisors first reported a position in Aldeyra Therapeutics in Q1 2018 and has held it in 31 quarters since.
  • Citadel Advisors's Aldeyra Therapeutics position peaked at $11M in Q1 2022.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.